ライフサイエンスコーパス: serum parathyroid hormone

1 fect of season on serum calcidiol but not on serum parathyroid hormone.

2 hydroxyvitamin D, and secondary increases in serum parathyroid hormone.

3 ic characteristics, dietary intakes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D]

4 Increases in serum parathyroid hormone accompanied skeletal healing,

5 Radioimmunoassays measured serum parathyroid hormone and 25-hydroxyvitamin D.

6 significant relationship between increasing serum parathyroid hormone and a positive MIBI scan.

7 yroid hormone secretion in vitro to decrease serum parathyroid hormone and calcium concentrations in

8 Serum parathyroid hormone and calcium were measured repe

9 serum albumin and inversely associated with serum parathyroid hormone and ferritin.

10 The calcimimetic drug R-568 reduces serum parathyroid hormone and ionized calcium concentrat

11 and alkaline phosphatases and inversely with serum parathyroid hormone and other bone resorption mark

12 e effect of dietary calcium and vitamin D on serum parathyroid hormone and vitamin D metabolites was

13 s, osteomalacia, hypophosphatemia, increased serum parathyroid hormone, and increased levels of the p

14 The serum parathyroid hormone concentration was inversely co

15 The mean serum parathyroid hormone concentration, which was 77+/-

16 eficiency rickets, bone mineral content, and serum parathyroid hormone concentration.

17 crease closely following the decrease in the serum parathyroid hormone concentration.

18 Higher serum parathyroid hormone concentrations showed a signif

19 Further, serum parathyroid hormone concentrations were significan

20 um (ie, increased urinary calcium, decreased serum parathyroid hormone, decreased bone resorption bio

21 Concentrations of serum parathyroid hormone in February-March were signifi

22 er, multiply by 0.25; P = .15), preoperative serum parathyroid hormone level (mean [SD], 114.5 [56.8]

23 if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mine

24 tive vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in pati

25 (RR 1.07 per 10 mg(2)/dl(2); P < 0.005) and serum parathyroid hormone levels greater than 495 pg/ml

26 However, very low serum parathyroid hormone levels have been associated wi

27 with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined

28 4.4-kb deletion of STX16 and who had normal serum parathyroid hormone levels until the age of 21 mo.

29 vels were performed in only 18% of patients, serum parathyroid hormone levels were obtained in only 1

30 ifested by larger parathyroid glands, higher serum parathyroid hormone levels, much lower bone minera

31 IRP technique without routine intraoperative serum parathyroid hormone measurement resulted in an exc

32 onfidence interval (CI) 1.1-2.8], increasing serum parathyroid hormone (OR 1.1 per 10 pg/mL 95% CI 1.

33 Primary outcomes were changes in serum parathyroid hormone (PTH) and 1,25-dihydroxyvitami

34 in 683 patients receiving hemodialysis with serum parathyroid hormone (PTH) concentrations higher th

35 he intravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concentrations in patien

36 tions in blood ionized calcium (iCa(2+)) and serum parathyroid hormone (PTH) concentrations were also

37 fat oxidation, potentially via regulation of serum parathyroid hormone (PTH) concentrations.

38 and Cdc73(+/-) mice also had increased mean serum parathyroid hormone (PTH) concentrations.

39 bly, the PT-Dicer(-/-) mice did not increase serum parathyroid hormone (PTH) in response to acute hyp

40 d Peptide (PTHrP), prevented the decrease in serum Parathyroid Hormone (PTH) induced by lactation, bu

41 parathyroidism is characterized by increased serum parathyroid hormone (PTH) level and parathyroid ce

42 al insufficiency is associated with elevated serum parathyroid hormone (PTH) levels (2 degrees HPT),

43 nd consequently miRNA, maintain normal basal serum parathyroid hormone (PTH) levels but do not develo

44 Serum parathyroid hormone (PTH) levels were elevated in

45 calcemia, anti-KRN23 antibodies, or elevated serum parathyroid hormone (PTH) or creatinine.

46 CLA treatment increased serum parathyroid hormone (PTH) significantly (p=0.0172)

47 Body weight, bone turnover markers, serum parathyroid hormone (PTH), and dietary intake were

48 Serum parathyroid hormone (PTH), calcium, phosphorus and

49 H)D] concentration >/=30 ng/mL) and decrease serum parathyroid hormone (PTH).

50 ntration below which there is an increase in serum parathyroid hormone (PTH).

51 used a sensitive radioimmunoassay to measure serum parathyroid hormone-related peptide (PTHrP) and a

52 cluded concentrations of serum 1,25(OH)(2)D, serum parathyroid hormone, serum creatinine, and serum e

53 -induced increases (P <0.01) in postprandial serum parathyroid hormone suppression.

54 D is more important than calcium in reducing serum parathyroid hormone, the source of dietary calcium

55 Serum parathyroid hormone was inversely correlated with

56 the relationship between scan positivity and serum parathyroid hormone was weaker.

57 .001) and the regression predicted that mean serum parathyroid hormone would be reduced in the elderl